Aspirin and Stroke: Uses, Dosing, and Bleeding Risk

Aspirin is one of the most important drugs in stroke medicine, but its role depends entirely on timing and stroke type. For ischemic strokes caused by blood clots, aspirin started within the first 48 hours reduces the chance of another stroke and lowers the risk of death. For long-term prevention after a stroke, it remains a front-line treatment. Yet aspirin can also cause the very thing it’s meant to prevent: it slightly raises the risk of hemorrhagic stroke, and for people who have never had a stroke, routine aspirin is no longer recommended by major guidelines. The relationship between aspirin and stroke is not a single story but several, and they sometimes pull in opposite directions.

How Aspirin Prevents Clots

When a blood vessel is injured or a clot starts forming, platelets rush to the site and clump together. They rely on an enzyme called cyclooxygenase-1 (COX-1) to produce thromboxane A2, a chemical signal that tells more platelets to aggregate. Aspirin permanently disables COX-1 by chemically altering it, so each platelet exposed to aspirin can no longer produce thromboxane for the rest of its roughly ten-day lifespan.¹ Because platelets cannot make new enzymes on their own, even a small daily dose of aspirin is enough to keep most of the circulating platelet pool suppressed. That mechanism is what makes aspirin useful after ischemic strokes, where a clot blocks blood flow to the brain.

The First 48 Hours After an Ischemic Stroke

The earliest and largest evidence for aspirin in acute stroke comes from two landmark trials run in the 1990s: the Chinese Acute Stroke Trial (CAST) and the International Stroke Trial (IST). A combined analysis of roughly 40,000 patients found that starting aspirin within 48 hours of symptom onset reduced recurrent ischemic strokes by about 7 per 1,000 patients treated and lowered the overall risk of further stroke or death in hospital by about 9 per 1,000.² The CAST trial alone showed a significant 14% reduction in mortality during the treatment period among aspirin-allocated patients compared with placebo.³

These numbers might sound modest on a per-patient basis, but across the millions of ischemic strokes that occur worldwide each year, the impact is enormous. Aspirin is cheap, widely available, and can be given immediately even in settings without advanced imaging or clot-retrieval capability. That combination of accessibility and proven benefit is why virtually every stroke guideline in the world recommends aspirin within 48 hours of an ischemic stroke, unless the patient has received a clot-dissolving drug called tPA, in which case antiplatelets are typically delayed 24 hours to reduce the risk of bleeding.⁴

Transient Ischemic Attacks and the Urgency Window

A transient ischemic attack, or TIA, produces stroke-like symptoms that resolve on their own, usually within minutes to an hour. The danger of a TIA is what comes next: the risk of a full ischemic stroke is highest in the first few days afterward. A time-course analysis of randomized trials found that aspirin started promptly after a TIA or minor stroke reduced the six-week risk of recurrent ischemic stroke by about 60%, and the risk of a disabling or fatal ischemic stroke by about 70%.⁵ The benefit was largest in the first two weeks, which is why emergency departments now emphasize loading patients with aspirin as soon as a TIA is diagnosed.

The effective dose range in these trials ran from 50 mg per day up to 325 mg per day, with no clear winner between low and high doses for preventing recurrence.⁶ What mattered most was speed. A TIA is often described as a “warning stroke,” and aspirin is the simplest tool to act on that warning immediately.

Adding a Second Antiplatelet After Minor Strokes

For patients who have had a minor ischemic stroke or a high-risk TIA, current evidence supports a short course of dual antiplatelet therapy, meaning aspirin combined with clopidogrel. The POINT trial enrolled nearly 5,000 patients and found that dual therapy reduced major ischemic events from about 6.5% with aspirin alone to about 5.0%, though it roughly doubled the rate of major hemorrhage (from about 0.4% to about 0.9%).⁷ A pooled analysis of both the POINT and CHANCE trials concluded that the benefit of adding clopidogrel was largely confined to the first 21 days after the event.⁸

That time limit matters. Continuing dual antiplatelet therapy beyond three weeks does not appear to prevent more strokes but does keep raising the bleeding risk. Most guidelines now recommend starting dual therapy as soon as possible after a qualifying event and stepping down to aspirin alone (or sometimes clopidogrel alone) after about three weeks. Blood pressure also seems to influence how well dual therapy works: a subgroup analysis from the POINT trial found that the stroke-prevention benefit was strongest in patients whose systolic blood pressure was below 140 mm Hg.⁹

Long-Term Prevention After a Stroke or TIA

Once past the acute phase, people who have had a non-cardioembolic ischemic stroke or TIA generally stay on an antiplatelet drug indefinitely to reduce the chance of another event. A meta-analysis of 11 placebo-controlled trials of aspirin monotherapy in secondary stroke prevention found a 13% relative risk reduction for the combined outcome of stroke, heart attack, and vascular death.¹⁰ Thirteen percent may not sound dramatic, but over years of use in a population at elevated risk, it translates into a meaningful number of strokes and deaths prevented.

Aspirin is not the only option for long-term prevention. Clopidogrel is an alternative, and accumulating evidence supports choosing between the two based on individual factors such as bleeding history, tolerance, and whether the patient has recently undergone a coronary stent procedure.¹¹ The point is that some antiplatelet drug should be on board. Aspirin remains the default largely because of decades of evidence, global familiarity, and its very low cost.

Why Aspirin Is No Longer Recommended to Prevent a First Stroke

For years, millions of healthy adults took a daily baby aspirin hoping to ward off heart attacks and strokes. That era is effectively over. In 2022, the U.S. Preventive Services Task Force updated its recommendation: adults 60 and older should not start aspirin for primary prevention of cardiovascular disease, and for those aged 40 to 59 with elevated cardiovascular risk, it should be an individualized decision rather than a routine one.¹²

The reasoning is straightforward. In people who have never had a stroke or heart attack, the absolute risk of a clot-related event is relatively low. Aspirin does reduce that risk somewhat, but it also raises the risk of gastrointestinal bleeding, intracranial bleeding, and hemorrhagic stroke. As people age, both the cardiovascular risk and the bleeding risk climb, but the bleeding risk climbs faster in relative terms, eventually tipping the balance against routine use. For someone who has already had a stroke, the math is completely different: the risk of another clot event is high enough that the benefit of aspirin clearly outweighs the bleeding hazard. The distinction between primary and secondary prevention is the most important thing to understand about aspirin and stroke.

The Hemorrhagic Stroke Trade-Off

Aspirin’s antiplatelet effect is a double-edged sword. The same mechanism that prevents clots from forming also makes it harder for the body to seal off a bleeding vessel inside the brain. A systematic review of observational studies found that long-term low-dose aspirin raised the overall relative risk of intracranial hemorrhage by about 40%.¹³ A large trial in healthy adults over 70 confirmed this: intracranial bleeding occurred in about 1.1% of the aspirin group compared with about 0.8% of the placebo group.¹⁴

In absolute terms, these numbers are small, which is why aspirin remains strongly recommended for people who already have cerebrovascular disease. But for healthy people at low baseline risk, even a small absolute increase in brain bleeding is hard to justify when the expected benefit is also small. This is the core of the primary prevention debate: aspirin reliably prevents some ischemic events and just as reliably causes some hemorrhagic ones, and whether you come out ahead depends on which risk is higher for you personally.¹⁵

When Aspirin Is the Wrong Antiplatelet

Not all strokes are caused by the kind of clot that aspirin can prevent. About one in five ischemic strokes is caused by atrial fibrillation, a heart rhythm disorder that allows blood to pool in the heart’s upper chambers and form clots that travel to the brain. These cardioembolic strokes require anticoagulant drugs, not antiplatelet drugs. An individual-patient meta-analysis found that oral anticoagulants roughly halved the rate of stroke compared with aspirin alone in patients with atrial fibrillation.¹⁶ A systematic review and separate analyses have confirmed that anticoagulation therapy is clearly superior to aspirin for stroke prevention in these patients.¹⁷

Despite this, aspirin was commonly prescribed to atrial fibrillation patients for decades, partly out of habit and partly from concern about anticoagulant-related bleeding. Current thinking is that aspirin is rarely the right choice for these patients, because it offers less protection against stroke and its own bleeding risks are not trivially lower than those of well-managed anticoagulant therapy.¹⁸ If you or a family member has been diagnosed with atrial fibrillation and is on aspirin alone, it is worth asking a doctor whether an anticoagulant would be more appropriate.

Aspirin Resistance

Some people take aspirin faithfully and still have strokes. Part of the explanation may be aspirin resistance, a condition where aspirin fails to adequately suppress platelet function. The exact prevalence is debated, but estimates suggest the resistance rate is high regardless of how it is measured.¹⁹ One study of patients with recurrent stroke symptoms while on aspirin found that about a third showed laboratory evidence of aspirin non-response, meaning their platelets were still clumping normally despite the drug.²⁰

Why this happens is not entirely clear. Some patients may not absorb the drug well, some may have genetic variations in the COX-1 enzyme, and in some cases nonsteroidal anti-inflammatory drugs like ibuprofen can compete with aspirin for the same enzyme binding site, blunting its effect. Routine platelet function testing is not currently standard practice, in part because there is no consensus on what to do when resistance is found. Switching to clopidogrel or adding a second agent are common clinical responses, but the evidence guiding those decisions remains thin.

Dose Questions: 81 mg Versus 325 mg

In North America, the two most common aspirin doses are 81 mg (often called “baby aspirin”) and 325 mg (a standard tablet). For stroke prevention, it has long been suspected that the lower dose works just as well with fewer side effects. A review of dose-comparison data found that low doses below 100 mg per day are effective for preventing ischemic stroke, and the side effect profile strongly favors the lower dose.²¹

The question was put to a head-to-head test in the ADAPTABLE trial, a large pragmatic study of patients with established cardiovascular disease. The trial found no significant difference in rates of death, heart attack, or stroke between the 81 mg and 325 mg groups, and no significant difference in major bleeding either, though there was heavy crossover from the 325 mg group to 81 mg during the study.²² In practice, most clinicians now default to 81 mg daily for long-term use. The higher dose is sometimes used briefly in acute settings or when dual therapy is being initiated, but for ongoing prevention, the lower dose has become standard.

Protecting the Stomach

Even at low doses, aspirin irritates the gastrointestinal lining and can cause ulcers and bleeding over time. For patients who need to stay on aspirin long-term, especially those on dual antiplatelet therapy, proton pump inhibitors (PPIs) can substantially reduce this risk. A meta-analysis found that PPIs decreased the odds of upper GI ulcers by about 84% and upper GI bleeding by about 73% in aspirin users.²³ In stroke patients specifically on dual antiplatelet therapy, PPI use reduced the risk of significant upper GI bleeding by about 37%, even in patients considered low risk for GI complications.²⁴

One nuance worth knowing: PPIs protect the upper GI tract but do not appear to reduce lower GI bleeding in aspirin users.²⁵ If you are on aspirin and developing new symptoms like dark or bloody stools, that warrants medical attention regardless of whether you are also taking a PPI.

The Danger of Stopping Aspirin Abruptly

Patients sometimes stop aspirin on their own, whether because of side effects, a planned dental procedure, or simply forgetting. This is riskier than most people realize. A case-control study found that in the four weeks after stopping aspirin, patients with multiple cerebrovascular risk factors had roughly a threefold increase in the odds of ischemic stroke compared with those who continued their medication.²⁶ The likely explanation is a rebound effect: when aspirin is withdrawn, newly produced platelets are suddenly uninhibited, and the system may temporarily swing toward being more clot-prone than it was before treatment started.

If you need to stop aspirin for surgery, the decision should involve the prescribing physician, who can weigh the bleeding risk of continuing against the stroke risk of stopping. For elective brain surgery, a panel of experts reached consensus that aspirin should generally be discontinued five to seven days before high-risk procedures but continued in patients at high thrombotic risk.²⁷ The key point for patients is to never stop aspirin without discussing it first.

Aspirin in Children After Stroke

Stroke in children is uncommon but not rare, and when it happens, treatment options are far less well studied than in adults. Aspirin is the most commonly used antiplatelet agent in pediatric stroke, mainly because clinicians have the most experience with it and no other agent has been proven superior.²⁸ Parents understandably worry about Reye’s syndrome, a rare but serious condition linked to aspirin use in children during viral illnesses. In the specific context of daily aspirin for stroke prevention, however, published reports of Reye’s syndrome are essentially absent. Most specialists consider the small theoretical risk of Reye’s acceptable when weighed against the sometimes substantial risk of another stroke in a child with known vasculopathy or unexplained infarction.

Global Gaps in Aspirin Use

Despite being one of the cheapest and most widely available drugs in the world, aspirin is dramatically underused for secondary stroke prevention in many countries. A study spanning 51 countries found that among people with a history of cardiovascular disease, only about 40% were using aspirin. In high-income countries, the figure was about 65%, but in low-income countries it dropped to roughly 17%.²⁹ The barriers are not mainly about cost. They involve fragmented healthcare systems, limited follow-up after a stroke event, lack of awareness among patients, and inconsistent prescribing. Adherence is also a problem even where aspirin is prescribed: older patients and those given higher doses are more likely to stop taking the medication over time.³⁰

The scale of this underuse is striking because aspirin’s secondary prevention benefit is well established and the drug costs pennies per day. Closing this gap, especially in low- and middle-income countries where stroke burden is growing fastest, is one of the simplest ways to prevent a large number of recurrent strokes worldwide.